Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma (BOTTOM)
Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma
Sponsor: Prof. Dr. med. Dirk Schadendorf
Terminated
lack of recruitment due to changed therapy options
This PHASE2 trial investigates Malignant Melanoma and is currently terminated or withdrawn. Prof. Dr. med. Dirk Schadendorf leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2019 — Nov 2020 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Dec 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Prof. Dr. med. Dirk Schadendorf
For direct contact, visit the study record on ClinicalTrials.gov .